# Signature Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/signature-diagnostics

- Industry: Biotechnology
- Headquarters: Potsdam, Germany
- Website: www.signature-diagnostics.de
- Total disclosed funding: $8M
- Latest round: Series C (Aug 12, 2008)
- Investors on record: 5

## About

Signature Diagnostics AG is a biotechnology firm focused on developing innovative diagnostic solutions for precision medicine, particularly in oncology, to enhance patient care and treatment efficacy.Signature Diagnostics AG specializes in the development of diagnostic solutions aimed at precision medicine in oncology. The company was founded in Potsdam, Germany, and in February 2015, it was acquired by Roche. The financial terms of the acquisition were not disclosed. The CEO and founder information is currently not available. The company has successfully completed a total of 3 deals, with its most recent funding round being a Series C, amounting to EUR 5.10 mn, led by EVP Capital Management and including investors such as BMP, Brandenburg Kapital, KfW Banking Group, and Oncomethylome Sciences BV.Signature Diagnostics AG focuses on the creation of advanced diagnostic tools primarily for oncology, enhancing the ability to diagnose and treat various cancers effectively. Their products are designed to support healthcare providers and researchers in identifying biomarkers and tailoring treatment strategies, contributing to better patient outcomes in cancer care.As the company is a subsidiary of Roche following its acquisition, detailed revenue figures specific to Signature Diagnostics AG are not publicly disclosed. However, the overall business model emphasizes long-term agreements for the supply of diagnostics, fostering ongoing relationships with healthcare institutions and supporting continuous advancements in diagnostic solutions.Following its acquisition by Roche, Signature Diagnostics AG plans to leverage its innovative diagnostic capabilities to expand into new markets, particularly in North America and Asia, by 2025. The recent funding of EUR 5.10 mn will be utilized to enhance product development and accelerate the launch of new diagnostic solutions aimed at oncology. Through these initiatives, the company aims to strengthen its position in the precision medicine landscape, addressing the evolving needs of healthcare providers and patients.

## Funding rounds

- Series C, Aug 12, 2008, $8M — EVP Capital Management, KfW Banking Group, BMP, Brandenburg Kapital, Oncomethylome Sciences BV

## Investors

- EVP Capital Management — Series C
- KfW Banking Group — Series C
- BMP (https://capitalatlas.ai/funds/bmp) — Series C
- Brandenburg Kapital (https://capitalatlas.ai/funds/brandenburg-kapital) — Series C
- Oncomethylome Sciences BV — Series C